Hosakote Nagaraj, MD
Cardiovascular Disease · Alabaster, ALNPI 1578510087
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,713 of the $32,965 with a category attached, or 71.9%. Integer Holdings Corporation accounts for 92.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $8,477 and has fallen 59.1% since, to $3,465 in 2025. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $370.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integer Holdings Corporation$30K
- Edwards Lifesciences$840
- Abbott$654
- Novartis$188
- Amgen$133
- Novo Nordisk$133
- plus $664 from 14 others
Across 6 payments — averaging $1316.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$8K
What the payments were for
- Consulting fees$23,71372%
- Travel & lodging$7,29022%
- Food & beverage$1,9636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integer Holdings Corporation | 15 | $30,355 |
| Edwards Lifesciences | 6 | $840 |
| Abbott | 15 | $654 |
| Novartis | 13 | $188 |
| Amgen | 9 | $133 |
| Novo Nordisk | 3 | $133 |
| Recordati_rare_diseases_inc. | 1 | $125 |
| Johnson & Johnson | 8 | $104 |
| Xeris Pharmaceuticals, Inc. | 1 | $88 |
| Pfizer | 4 | $72 |
| Abiomed | 2 | $44 |
| Angiodynamics, Inc. | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Merck | 2 | $37 |
| Chiesi USA, Inc. | 1 | $23 |
| Acutus Medical, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Bayer | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAFARI$3,938
- AMPLATZER GUIDEWIRE$3,850
- CIRCULO GUIDEWIRE$3,325
- SAFARI2$3,063
- SAFARI GUIDEWIRE$2,975
- PREFORMED GUIDEWIRE$2,100
- PRE-FORMED GUIDEWIRE$1,925
- SAFARI 2$1,750
- SAFARI 2 EXTRA SUPPORT$1,750
- CPS COURIER GUIDEWIRE$1,050
- AXESSIO GUIDEWIRE$1,050
- CHARTER GUIDEWIRE$1,050
- CARDIAC AND PERIPHERAL GUIDEWIRE FAMILY$1,050
- MYOPORE$963
- AMPLATZER WIRE$827
- Edwards SAPIEN 3 Transcatheter Heart Valve$694
- MitraClip$241
- Sylvant$125
- AMPLATZER AMULET$108
How this compares
$32,965 in reported general payments places this provider in the 90th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 192 | $186,351 |
| EntrestoSacubitril/Valsartan | 151 | $151,532 |
| BrilintaTicagrelor | 85 | $58,514 |
| XareltoRivaroxaban | 23 | $31,347 |
| Repatha SureclickEvolocumab | 29 | $27,965 |
| Isosorbide Dinitrate | 59 | $11,776 |
| Metoprolol Succinate | 498 | $7,438 |
| Amiodarone Hcl | 100 | $4,143 |
| ClopidogrelClopidogrel Bisulfate | 231 | $2,741 |
| Ranolazine ErRanolazine | 26 | $2,637 |
| Atorvastatin Calcium | 187 | $2,635 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 134 | $2,187 |
| Losartan Potassium | 173 | $2,066 |
| Carvedilol | 244 | $2,053 |
| Amlodipine Besylate | 230 | $1,543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $72 | $186,351192 claims |
| NovartisEntresto | $188 | $151,532151 claims |
| Johnson & JohnsonXarelto | $104 | $31,34723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Alabaster
- David FienoAlabaster$421K
- Dennis ThomasMobile$894K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Ajit NaiduFlorence$66K
- Mahomed SalameAnniston$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.